Llwytho...
An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
Patients suffering from pancreatic neuroendocrine tumors (pNETs) are now candidates to receive novel approved drugs that have demonstrated benefit in disease control rate and delay the time taken for tumor progression in Phase III clinical trials; for example, sunitinib, everolimus and lanreotide. T...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Rare Cancers Ther |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Springer Healthcare
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4837935/ https://ncbi.nlm.nih.gov/pubmed/27182476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-015-0007-6 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|